New US acquisition for Nestlé Health Science will strengthen Brain Health and Metabolic Health portfolios with new medical foods

Tue Feb 26, 2013 1:15am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130226:nHUGcXFH



Nestlé S.A. / New US acquisition for Nestlé Health Science will strengthen Brain Health and
Metabolic Health portfolios with new medical foods . Processed and transmitted by Thomson Reuters
ONE. The issuer is solely responsible for the content of this announcement.

Nestlé Health Science, a fully owned subsidiary of Nestlé, has agreed to acquire the business of
Pamlab http://www.pamlab.com/ , a US-based company with an innovative portfolio of medical food
products for use under medical supervision in the nutritional management of patients with mild
cognitive impairment, depression and diabetic peripheral neuropathy.

Strategic fit
The acquisition further strengthens Nestlé Health Science's capacity to deliver personalised
healthcare to address chronic medical conditions through nutrition, especially in the areas of
metabolic health and brain health.

"The acquisition of the Pamlab business is aligned with our strategic ambition to provide
science-based nutritional solutions for people with chronic medical conditions. Pamlab will
particularly strengthen our brain health platform and provide us an additional foothold in
metabolic health in the US," said Luis Cantarell, Nestlé Health Science President and Chief
Executive Officer. 

"By leveraging our nutrition heritage and US operations with Pamlab's proven expertise in medical
foods and strong sales force capabilities, together we can play a key role in helping to manage
certain chronic diseases and improve the quality of patients' lives," he added.

Commercialised products that improve quality of life
Pamlab's portfolio of prescription medical food products for use under medical supervision
includes Metanx, one of their key products that is formulated to meet the distinct nutritional
requirements of patients with diabetes to help restore the metabolic processes associated with
peripheral neuropathy. 

This serious condition is common among those with Type 2 Diabetes, where the patient's peripheral
blood flow has been compromised and their nerves damaged. 

Pamlab also makes Deplin, a medical food specifically formulated to provide necessary nutritional
support for certain people on prescribed antidepressant therapy for clinical depression. 

Deplin contains l-methylfolate, the active ingredient of folate, to help balance three
neurotransmitters associated with mood: serotonin, dopamine and norepinephrine.

In addition, the company produces CerefolinNAC, a medical food to help address distinct metabolic
nutritional needs associated with mild cognitive impairment.

A common purpose
"We are excited to join forces with Nestlé Health Science, and we share their commitment to
personalised nutrition," said Eric Wingerter, Pamlab President and Chief Executive Officer.

"With their support, we will accelerate the development and deployment of our innovative
nutritional solutions for people with chronic metabolic and neurologic conditions. 
"We are united by a common purpose, and a common culture, founded on our passion for patients to
make a difference in people's lives." 

Building on ambition towards science-based nutritional solutions
Nestlé Health Science's core business provides nutritional solutions for people with specific
dietary needs related to illness or disease states in the area of ageing medical care, critical
care and surgery, and paediatric medical care. 

The company is also developing new approaches to chronic diseases in the areas of gastrointestinal
(GI) health, metabolic health and brain health. 

In 2012 Nestlé Health Science agreed to form a 50/50 joint venture named Nutrition Science
Partners, Ltd to develop nutritional and medicinal products derived from botanical plants to
address gastrointestinal disorders. This transaction is subject to regulatory approval.

Other acquisitions and partnerships include: Prometheus Laboratories, a U.S. firm specialising in
diagnostics and licensed speciality pharmaceuticals in GI and oncology; Vitaflo, a provider of
clinical nutritional solutions for infants, children and adults with genetic disorders that affect
how food is processed by the body; and a minority investment in U.S firm Accera, specialising in
medical foods intended for the clinical dietary management of mild to moderate Alzheimer's
disease.

Terms of acquisition
The terms of Nestlé Health Science's acquisition of Pamlab are not being disclosed. The
transaction is subject to regulatory approval.

Media enquiries
Tel: +41 21 924 2200
Email: mediarelations@nestle.com mailto:mediarelations@nestle.com


---------------------------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Nestlé S.A. via Thomson Reuters ONE


HUG#1680988



 --- End of Message --- 

Nestlé S.A.
Avenue Nestlé 55 Vevey 

WKN: 887208;ISIN: CH0038863350;